



## AMGEN QUICK FACTS

### Global Headquarters

Thousand Oaks, California

### Staff

Nearly 20,000 worldwide

### Stock Listing

NASDAQ: AMGN

### 2015 Financial Highlights

Total revenue: \$21.7 billion

Product sales: \$20.9 billion

R&D expense: Approximately \$4.0 billion

### Amgen Korea Leadership

Sang Noh, General Manager

### Amgen Korea Address/Phone

14th Floor, Seoul International Tower

203, Teheran-ro, Gangnam-gu

Seoul, 06141 Korea

Office: (82) 2-3434-4800

For more information on Amgen Inc., visit

[www.amgen.com](http://www.amgen.com).

For more information on Amgen Korea, please visit

[www.amgenkorea.kr](http://www.amgenkorea.kr).

## AMGEN IN KOREA

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen opened an affiliate in Korea in November, 2015, to market its innovative medicines for patients suffering from serious illnesses. Amgen's entry into Korea is expected to bring new jobs, more clinical trials and innovative therapies for grievous illness to patients in Korea. Amgen also looks forward to being an active member of the local biotechnology community and helping to advance the growth of this industry in Korea.

## COMMITMENT TO HELPING IMPROVE HEALTHCARE IN KOREA

Korea's healthcare industry has become a globally competitive industry with a large pool of resources, advanced education and diagnostic systems. Korean healthcare professionals are regarded as one of the most advanced groups in both clinical practices and clinical research projects. Amgen's entry into Korea is in keeping with the Company's growth plans in important markets around the world. Amgen's expansion into Korea reflects the Company's interest in increasing patient access to its medicines, in support of Amgen's mission to serve patients.

Amgen's initial priorities in Korea will include:

- Continuing to invest in clinical trials in Korea. Amgen has conducted 29 study projects to date in Korea, and 18 of these studies are ongoing.
- Advancing its clinical pipeline, which includes treatments for bone disease, cardiovascular, hematology/oncology and inflammation.
- Being an active member in the local biotechnology industry to encourage mutual growth and to create a positive environment.

## ABOUT BIOTECHNOLOGY MEDICINES

The biotechnology revolution has generated a new class of treatments: biologic medicines. These are therapies which, in general, are derived from living organisms, and include therapeutic proteins, DNA vaccines, monoclonal antibodies and fusion proteins. Through genetic engineering, living cells are used to produce proteins to treat a range of illnesses.

## AN INTERDISCIPLINARY APPROACH TO R&D

For more than 30 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. We focus on pioneering treatments for serious illness. Our R&D organization has cultivated expertise in multiple treatment modalities—large-molecule proteins, small molecules and antibodies—allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target.

Amgen has a robust pipeline and has expanded its clinical program across the Asia Pacific region to support the company's increasingly complex and global clinical trials. Korea offers excellent professionals with clinical and scientific expertise, as well as large and diverse patient populations with the potential to benefit from Amgen's therapies.

## CLINICAL TRIALS

Amgen applies the highest standards of scientific research to all its products. We are committed to investing in clinical trials to ensure that our products are recognized by the Korean government, medical professionals and patients in Korea.

Amgen, since starting to prepare the first clinical trial in Korea in 2008, has had 29 study projects, of which 18 studies are currently ongoing in Korea, with more than 1,200 enrolled subjects across 171 clinical trial sites. Amgen has a robust pipeline of medicines in clinical development and is focused on delivering important new therapies for the treatment of serious illnesses to patients around the world, including in Korea. Amgen invested 25 billion KRW for clinical trials in Korea over the past 5 years.

## PREPARING FOR COMMERCIAL PRESENCE IN KOREA

Amgen is currently working to ensure that some of its most vital medicines are made available to patients suffering from serious illness in Korea. The Ministry of Food and Drug Safety approved Kyprolis as a treatment for multiple myeloma and Blincyto as a treatment for acute lymphoblastic leukemia in November 2015. Amgen plans to make more diverse medicines available to patients in Korea as soon as possible.

## BIOSIMILARS

Biosimilars have an essential role in providing an important option for some patients, provided they are safe and effective and the intellectual property of the innovator is protected. Amgen, a pioneer in the field of biologic medicines, is developing and plans to commercialize biosimilars of non-Amgen products.

Amgen has nine biosimilars in development. The initial three biosimilars (adalimumab, trastuzumab, bevacizumab) are all in pivotal studies, two additional biosimilars are clinical ready and four are in process development.